DF-9001 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DF-9001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DF-9001 overview
DF-9001 is under development for the treatment of solid tumor, non-small cell lung cancer, head and neck squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, metastatic renal cell carcinoma. The drug candidate is tri-specific monoclonal antibody targeting cells expressing Epidermal Growth Factor Receptor (EGFR) being developed based on Tri-specific, NK cell Engager Therapy (TriNKET) platform.
The drug candidate was also under development for the treatment of esophageal adenocarcinoma, gastric cancer, metastatic pancreatic cancer and metastatic colorectal cancer.
Dragonfly Therapeutics overview
Dragonfly Therapeutics (Dragonfly) is a clinical-stage biotechnology company. It discovers, develops, and commercializes novel immune therapies to treat autoimmune disease, oncology, neuro-inflammation, and others. The company utilizes its proprietary platform, TriNKET, for developing its pipeline products which include DF1001, DF6002, DF9001, and DF6215 drug candidates for the treatment of solid tumors. Dragonfly is also developing various other drug candidates for in collaboartion with companies such as Bristol Myers Squib, Merck, Abbvie, and Gilead. Dragonfly is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DF-9001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
